Loading…

Topical application of Gallic acid suppresses the 7,12-DMBA/Croton oil induced two-step skin carcinogenesis by modulating anti-oxidants and MMP-2/MMP-9 in Swiss albino mice

•Topical application of Gallic acid (GA), a dietary antioxidant delays the DMBA/Croton oil induced skin carcinogenesis.•Topical application of GA normalized the altered levels of serum LDH-isoenzymes profile, enzymatic and non-anti-oxidants.•GA treatment suppresses the MMPs and collagen production i...

Full description

Saved in:
Bibliographic Details
Published in:Food and chemical toxicology 2014-04, Vol.66, p.44-55
Main Authors: Subramanian, Vimala, Venkatesan, Balaji, Tumala, Anusha, Vellaichamy, Elangovan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Topical application of Gallic acid (GA), a dietary antioxidant delays the DMBA/Croton oil induced skin carcinogenesis.•Topical application of GA normalized the altered levels of serum LDH-isoenzymes profile, enzymatic and non-anti-oxidants.•GA treatment suppresses the MMPs and collagen production in two-step skin carcinogenesis.•Underlying mechanism of action of GA probably due to its antioxidant & anti-fibrotic activity. Gallic acid (GA – 3,4,5-trihydroxybenzoic acid), a dietary anti-oxidant has been shown to inhibit cancer cell growth in in vitro. Herein, we investigated the in vivo chemo preventive activity of GA on 7,12-Dimethylbenz[a]anthracene (DMBA)/Croton oil induced two-step skin carcinogenesis in Swiss albino mice. Skin tumor incidence and tumor volume were recorded during the 16weeks of experimental period. In addition, LDH-isozyme shift, skin collagen content, activities of matrix metalloproteinases (MMP-2/MMP-9) enzymes and enzymatic and non-enzymatic antioxidant were studied in the skin and serum of experimental mice. Tumor incidence was significantly increased in the DMBA/Croton oil induced mice (100%; p
ISSN:0278-6915
1873-6351
DOI:10.1016/j.fct.2014.01.017